Crosstalk between Inflammatory Bowel Disease Proteins and Neuroinflammatory Proteins for Understanding Involvement of Gut-Brain Axis in Parkinson’s Disease and Identified Drug Receptors: In-Silico Approach

2021 ◽  
Vol 16 (12) ◽  
pp. 196-208
Author(s):  
Nitu Dogra ◽  
Ruchi Jakhmola-Mani ◽  
Deepshikha Katare Pande

Parkinson’s disease (PD) is a chronic, progressive and second most prevalent neurological disorder affecting the motor system. It has been found that people suffering with inflammatory bowel disease (IBD) are 22% more prone to PD. In the current study, we have framed a hypothesis and deciphered protein-protein interaction network between the IBD and PD and therefore, have proposed a role of gut-brain axis in PD. Text mining for retrieval of Differentially Expressed protein (DEPs; specific to Homo sapiens) associated with PD and IBD was done using Science Direct, Pub Med Central, Sci ELO and JSTOR. The protein interaction network was constructed in Cytoscape (version 3.7.1) by using above 58 DEPs. The generated master network was further analyzed using BiNGO plugin for retrieval of overrepresented biological processes in IBD-PD pathologies. Hub nodes were also generated in the network. In the present study the gutbrain hypothesis was designed which demonstrates the series of protein interactions that ought to link IBD to PD. Major proteins involved in this connection were LRRK2, APOE, SNCA, IL6, HIF-1α, ABCA, TLR4, CREB1, IL10, ADORA2A, DRD2, INOS, CCL2, SLC6A3 and CASP3. These proteins could be used as druggable targets to halt the progression of PD pathogenesis initiating via IBD. The common biological pathways linking both the pathologies were found to be HIF-signaling, Cytokines interactions, JAK-STAT pathway, Cholesterol metabolism, cAMP mediated signaling and apoptosis. This study also suggests the role ABC transporters and APOE in linking IBD and PD via disturbance of cerebral homeostasis.

Gut ◽  
2020 ◽  
pp. gutjnl-2020-322429 ◽  
Author(s):  
Ho-Su Lee ◽  
Evy Lobbestael ◽  
Séverine Vermeire ◽  
João Sabino ◽  
Isabelle Cleynen

Inflammatory bowel disease and Parkinson’s disease are chronic progressive disorders that mainly affect different organs: the gut and brain, respectively. Accumulating evidence has suggested a bidirectional link between gastrointestinal inflammation and neurodegeneration, in accordance with the concept of the ‘gut–brain axis’. Moreover, recent population-based studies have shown that inflammatory bowel disease might increase the risk of Parkinson's disease. Although the precise mechanisms underlying gut–brain interactions remain elusive, some of the latest findings have begun to explain the link. Several genetic loci are shared between both disorders with a similar direction of effect on the risk of both diseases. The most interesting example is LRRK2 (leucine-rich repeat kinase 2), initially identified as a causal gene in Parkinson's disease, and recently also implicated in Crohn’s disease. In this review, we highlight recent findings on the link between these seemingly unrelated diseases with shared genetic susceptibility. We discuss supporting and conflicting data obtained from epidemiological and genetic studies along with remaining questions and concerns. In addition, we discuss possible biological links including the gut–brain axis, microbiota, autoimmunity, mitochondrial function and autophagy.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rita Lippai ◽  
Apor Veres-Székely ◽  
Erna Sziksz ◽  
Yoichiro Iwakura ◽  
Domonkos Pap ◽  
...  

AbstractRecently the role of Parkinson’s disease 7 (PARK7) was studied in gastrointestinal diseases, however, the complex role of PARK7 in the intestinal inflammation is still not completely clear. Expression and localization of PARK7 were determined in the colon biopsies of children with inflammatory bowel disease (IBD), in the colon of dextran sodium sulphate (DSS) treated mice and in HT-29 colonic epithelial cells treated with interleukin (IL)-17, hydrogen peroxide (H2O2), tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β or lipopolysaccharide (LPS). Effect of PARK7 on the synthesis of IBD related cytokines was determined using PARK7 gene silenced HT-29 cells and 3,4,5-trimethoxy-N-(4-(8-methylimidazo(1,2-a)pyridine-2-yl)phenyl)benzamide (Comp23)—compound increasing PARK7 activity—treated mice with DSS-colitis. PARK7 expression was higher in the mucosa of children with Crohn’s disease compared to that of controls. While H2O2 and IL-17 treatment increased, LPS, TNF-α or TGF-β treatment decreased the PARK7 synthesis of HT-29 cells. PARK7 gene silencing influenced the synthesis of IL1B, IL6, TNFA and TGFB1 in vitro. Comp23 treatment attenuated the ex vivo permeability of colonic sacs, the clinical symptoms, and mucosal expression of Tgfb1, Il1b, Il6 and Il10 of DSS-treated mice. Our study revealed the role of PARK7 in the regulation of IBD-related inflammation in vitro and in vivo, suggesting its importance as a future therapeutic target.


2019 ◽  
Vol 267 (8) ◽  
pp. 2207-2213 ◽  
Author(s):  
Malvyne Rolli-Derkinderen ◽  
Laurène Leclair-Visonneau ◽  
Arnaud Bourreille ◽  
Emmanuel Coron ◽  
Michel Neunlist ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document